Published in Cancer Weekly, March 24th, 1997
Saquinavir belongs to a class of drugs known as protease inhibitors.
In 1995, it became the first HIV protease inhibitor to gain approval by the U.S. Food and Drug Administration (FDA). Patients and doctors have found, however, that getting enough saquinavir out of the digestive system to reach HIV infected T cells in the bloodstream is a difficult task.
There are many reasons why...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.